NOVOGEN LIMITED
(ASX: NRT)
![[asxreleasenovogen20131021002.gif]](https://capedge.com/proxy/6-K/0001075880-13-000092/asxreleasenovogen20131021002.gif)
ASX RELEASE
21 October 2013
Purchase of Convertible Security
Novogen today announced that it has under the Convertible Securities
Agreement referred to in its announcement of 4 July 2013, issued a second
convertible security to its US based institutional investor. This will raise
another $1 million to fund Novogen’s continued drug development program.
The terms of the Convertible Securities Agreement remain unchanged.
Dr Graham Kelly, Novogen CEO said. “We recently announced the acquisition
of a second drug technology platform known as anti-tropomyosins. The funds
raised through the issuance of this convertible security will be applied to the
development of that drug platform.”
About Novogen
Novogen Ltd is a public Australia biotechnology company whose shares trade
on both the Australia Stock Exchange (symbol ‘NRT’) and NASDAQ (symbol
‘NVGN’). The company is based in Sydney, Australia, with an office in Ithaca,
NY, USA. The Company is focused on the development of drug strategies
that will deliver personalized chemotherapy based on the effective elimination
of cancer stem cells and somatic cancer cells across a range of genotypes.
Yours truly,
Lionel Mateo
Company Secretary
NOVOGEN LTD – ACN 063 259 754
16-20 Edgeworth David Ave, Hornsby, NSW, 2077
P: +61 (0) 2 9476 0344 - F: +61 (0) 2 9476 0388
www.novogen.com